Inactive Instrument

ProLung, Inc. Share Price

LUNG

US74348P2092

Healthcare Facilities & Services

Prolung, Inc. is a development-stage medical technology company specializing in predictive analytic, early stage lung cancer risk testing, which refer to as the ProLung Test. The Company's ProLung Test is developed to immediately assess the risk of malignancy in lung nodules found in the chest by a Computed Tomography (CT) scan. The Company's Lead Product is ProLung Test, which is designed to evaluate the risk of lung cancer in patients with lung nodules in well-controlled clinical trials. The ProLung Test includes components, such as ProLung System and ProLung Test Kit. ProLung System consists of the probe, scanner, tower, monitor, and keyboard which are all medical grade components. This component is available for sale in English, French, German, Spanish, and Italian versions. ProLung Test Kit includes six diaphoretic electrodes, one probe tip and one moistening sponge.

Employees

Sector

Healthcare Facilities & Services

More about the company

Stock Market
Stocks
LUNG Stock

The best tools reserved for subscribers to boost the performance of your investments!

22/05/23	ProLung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
17/04/23	ProLung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
16/04/23	ProLung, Inc. Auditor Raises 'Going Concern' Doubt	CI
14/11/22	ProLung, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
15/08/22	ProLung, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
23/05/22	ProLung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
15/04/22	ProLung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
14/04/22	ProLung, Inc. Auditor Raises 'Going Concern' Doubt	CI
12/11/21	ProLung, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
07/10/21	IONIQ Sciences, Inc. Announces the Appointment of Aaron B. Dorny to Its Board of Directors	CI
16/08/21	Prolung, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
24/05/21	Prolung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
03/05/21	Prolung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI

08/12/20	Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company Growth	GL
30/11/20	Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD	GL
10/11/20	Pulmonx Reports Third Quarter 2020 Financial Results	GL
03/11/20	Pulmonx to Present at Upcoming Investor Conferences	GL
02/11/20	Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option for Severe Emphysema (COPD)	GL

Manager	Title	Age	Since
Jared Bauer CEO	Chief Executive Officer	44	04/09/2018
Michael Garff CEO	Chief Executive Officer	42	27/06/2018
Jennifer K. Zimmons IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Michael Garff BRD	Director/Board Member	42	27/06/2018
Jared Bauer BRD	Director/Board Member	44	31/08/2018
David Nielsen BRD	Director/Board Member	53	09/06/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROLUNG, INC.	-.--%	-.--%	-	-	0
NATERA, INC.	+0.58%	+0.53%	+95.39%	+457.61%	38.87B
LABCORP HOLDINGS INC.	+0.50%	+2.37%	+16.26%	+33.21%	23.24B
SONIC HEALTHCARE LIMITED	+0.64%	+3.01%	-20.75%	-38.52%	7.55B
RADNET, INC.	-1.27%	-5.20%	+8.18%	+82.59%	4.89B
DR. LAL PATHLABS LIMITED	-2.61%	-0.32%	+12.36%	+42.73%	2.93B
NEOGENOMICS, INC.	-1.55%	+3.54%	+134.13%	-14.91%	1.9B
GENEDX HOLDINGS CORP.	+2.90%	-3.29%	-18.48%	+756.68%	1.88B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-5.48%	+7.11%	-10.82%	-62.13%	1.8B
FLEURY S.A.	+7.73%	+1.04%	+31.35%	+8.15%	1.76B
Average	+0.14%	+0.42%	+27.51%	+140.60%	9.42B
Weighted average by Cap.	+0.37%	+0.92%	+50.23%	+236.92%

ProLung, Inc. Share Price

Stocks

LUNG

US74348P2092

Healthcare Facilities & Services

Latest news : ProLung, Inc.

Press Releases: ProLung, Inc.

Managers and Directors: ProLung, Inc.

Medical & Diagnostic Laboratories

Company Profile